SCHEMBL876364

SCHEMBL876364

OCc1ccc(Oc2cccc(C(F)(F)F)c2)cc1C(F)(F)F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.47
MAPK14 Q16539 1/20 0.45
MAOB P27338 1/20 0.45
AOC3 Q16853 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
KIF11 P52732 1/20 0.44
EPAS1 Q99814 1/20 0.44
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 1/20 0.43
TLR8 Q9NR97 1/20 0.42
TLR7 Q9NYK1 1/20 0.42
AR P10275 2/20 0.42
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 2/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
MAPT P10636 1/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL694728 0.86 LTA4H (0.50) LTA4HMAPK14ARNR1H2NR1H3
SCHEMBL876543 0.85 TLR8 (0.48) LTA4HMAPK14MAOBAOC3SMN1; SMN2
SCHEMBL16199417 0.85 LTA4H (0.45) LTA4HMAPK14MAOBAOC3SMN1; SMN2
SCHEMBL883737 0.85 PPARG (0.50) LTA4HMAPK14MAOBAOC3SMN1; SMN2
SCHEMBL15096325 0.84 AR (0.60) ALDH1A1L3MBTL1ARNR1H2NR1H3
SCHEMBL875891 0.83 CYP1A2 (0.48) LTA4HMAPK14MAOBAOC3SMN1; SMN2
SCHEMBL3113955 0.81 MAOB (0.39) LTA4HMAPK14MAOBAOC3SMN1; SMN2
SCHEMBL8636487 0.81 THRA (0.46) LTA4HMAPK14MAOBAOC3KIF11
SCHEMBL875576 0.81 LTA4H (0.58) LTA4HMAPK14MAOBSMN1; SMN2KIF11
SCHEMBL27579381 0.80 LTA4H (0.59) LTA4HMAPK14SMN1; SMN2KIF11ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
EP-2619203-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES Glaxo Group Limited (GB) 2013-07-31 EP disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 LTA4H 8/4885MAPK14 1481/4885MAOB 510/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 LTA4H 8/4885MAPK14 1481/4885MAOB 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.